Loading cancer entity…
Loading cancer entity…
Clinical trials
10,627 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,641)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07048353 | CD30 CAR-T in the Treatment of CD30 Positive Lymphoma(CAR-T，MTD) | suspended | Early Phase 1 | 15 | Shandong Qilu Cell Therapy Engineering Technology Co., LtdINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06691685 | A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma. | suspended | Early Phase 1 | 24 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| 1 |
| Jul 22, 2026 |
| clinicaltrials |
| NCT06663046 | Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma | suspended | Early Phase 1 | 30 | Wondercel Biotech (ShenZhen)INDUSTRY | 1 | May 7, 2026 | clinicaltrials |
| NCT06235281 | Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)(PLIGHT) | suspended | Early Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04697290 | CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients. | suspended | Early Phase 1 | 12 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Feb 14, 2022 | clinicaltrials |
Data updated yesterdaySource updated Sep 28, 2026source: clinicaltrials